Transgene and NEC Bio enter license agreement

3 April 2026

French biotech company Transgene (Euronext Paris: TNG), which develops virus-based immunotherapies for the treatment of cancer, and NEC Bio, a wholly owned subsidiary of NEC Corporation (TYO: 6701), a leader in IT, network and AI technologies, have signed a license agreement to advance the clinical development of TG4050, an individualized neoantigen therapeutic vaccine (INTV) in the adjuvant treatment of resected HPV-negative head and neck cancer. Transgene shares fell 3.4% to 0000.74 euros following the announcement.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

More on this story...

Biotechnology

Transgene advances lead cancer vaccine TG4050

27 March 2025

Biotechnology

Transgene to trial immuno-oncology combination as first-line cancer therapy

26 April 2017

Biotechnology

Transgene signs deal to develop multifunctional oncolytics

3 October 2017

More ones to watch >

Company Spotlight

BeOne Medicines

A Nasdaq-listed oncology biotechnology company developing and commercializing cancer therapies across hematologic malignancies and solid tumors. BeOne Medicines operates a global development and commercial platform spanning North America, Europe and Asia.